Discover 720 paid clinical trials in Vancouver, British Columbia. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 720
FeaturedActive & Responsive
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
for
Solid Tumor
Location: Vancouver, La Jolla CA, Dallas PA, Chicago IL,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT06619587
Phase1, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Get alerts for new trials in your area by subscribing now
Featured
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
for
Hemophilia A
Location: Vancouver, Sacramento CA, Iowa City IA, Indianapolis IN,
Sponsor: Hoffmann-La Roche
Sex: Male
Age: 2 - 59
Code: NCT05987449
Phase1, Phase2, Recruiting
Featured
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
for
Alzheimers Disease
Location: Richmond, Kelowna, Portland OR, Oakland CA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 50 - 70+
Code: NCT07177352
Phase3, Recruiting
Featured
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
for
Alzheimers Disease
Location: Richmond, San Francisco CA, Los Angeles CA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 50 - 70+
Code: NCT07169578
Phase3, Recruiting
Featured
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
for
Obesity or Overweight
Location: Surrey, Portland OR, Calgary, Walnut Creek CA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07351045
Phase3, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer